Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tesar, V.
Right arrow Articles by Merta, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tesar, V.
Right arrow Articles by Merta, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: V2-V4
© 2003 European Renal Association-European Dialysis and Transplant Association

Current treatment strategies in ANCA-positive renal vasculitis—lessons from European randomized trials

V. Tesar, Z. Ríhová, E. Jancová, R. Rysavá and M. Merta

First Medical Department, First Medical Faculty, Charles University, Prague, Czech Republic

Antineutrophil cytoplasmic antibody (ANCA)-positive renal vasculitis is the most common cause of rapidly progressive (crescentic) glomerulonephritis. Its life-threatening natural course may be modified substantially by current treatment modalities. The European Vasculitis Study Group (EUVAS) developed a subclassification of ANCA-positive vasculitides based on the disease severity at presentation, and have organized (so far) two waves of clinical trials. The first wave of randomized clinical trials had the aim of optimizing the existing therapeutic regimens; the second wave concentrated on testing some newer therapeutic approaches. Here, the design and available results of the first wave and the design of some second wave trials are reviewed briefly. The potential of the new targeted approaches (e.g. anti-tumour necrosis factor therapy) is also briefly mentioned.

Keywords: anti-neutrophil cytoplasmic antibodies; treatment; vasculitis

Correspondence and offprint requests to: Vladimír Tesar, MD, PhD, First Medical Department, First Medical Faculty, Charles University, U nemocnice 2, Praha 2, 128 08, Czech Republic. E-mail: tesarv{at}beba.cesnet.cz


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
S. L. Hogan, R. J. Falk, P. H. Nachman, and J. C. Jennette
Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis.
Ann Intern Med, March 7, 2006; 144(5): 377 - 378.
[Full Text] [PDF]

Home page
 ChestHome page
S. K. Frankel, G. P. Cosgrove, A. Fischer, R. T. Meehan, and K. K. Brown
Update in the diagnosis and management of pulmonary vasculitis.
Chest, February 1, 2006; 129(2): 452 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
S K Frankel, G P Cosgrove, and K K Brown
Small vessel vasculitis of the lung
Chronic Respiratory Disease, April 1, 2005; 2(2): 75 - 84.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.